Alnylam Pharmaceuticals, Inc.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases with high unmet need. Alnylam’s pipeline of investigational medicines includes four late-stage product candidates, with one filed for regulatory approval. Alnylam employs over 800 people across U.S. and Europe, with headquarters in Cambridge, MA. For more information please visit www.alnylam.com.